Physician profile
Jason A Hampl
NPI 1669498010
$10,095.39
in general payments reported to CMS, 2019-2025
56 companies · $1,910 in 2025
The $1,910 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $1,170 · 2021: $1,539 · 2022: $1,704 · 2023: $1,298 · 2024: $1,738 · 2025: $1,910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,938 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,938.17 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,406.53 | 2019-2025 | |
| Lilly USA, LLC | $807.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $739.84 | 2019-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $657.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $597.39 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $593.44 | 2019-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $523.82 | 2019-2025 | |
| Glaxosmithkline, LLC. | $503.18 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $403.85 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $327.97 | 2019-2025 | Xarelto, Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $278.17 | 2022-2025 | |
| Allergan, INC. | $247.03 | 2019-2020 | |
| Abbott Laboratories | $237.77 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $218.87 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $191.17 | 2022-2025 | Rexulti |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Hampl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.